💸 The Tape

The FDA just gave the psychedelic therapeutics industry two things it has been asking for since the sector's inception: a finalized regulatory rulebook and a seat at the table. For the companies racing toward the first psychedelic drug approvals in American history, the timing could not be better.

On Monday, the agency published its finalized guidance — "Psychedelic Drugs: Considerations for Clinical Investigations" — providing formal recommendations for sponsors developing therapies based on psilocybin, LSD, MDMA, and related compounds. Simultaneously, the FDA announced a public hearing on September 14 to gather perspectives on the "potential future therapeutic use" of psychedelic drug products in supervised and supportive settings.

Together, the two announcements represent the clearest signal yet that the FDA is not merely tolerating psychedelic drug development — it's building the infrastructure to regulate an approved market.

What the Guidance Actually Says

The finalized document builds on the draft version first published in 2023, incorporating public comments received over the intervening years. Its core message: psychedelic programs face "the same regulations and same evidentiary standards for approval as other drug development programs" — but the agency acknowledges these compounds present "unique challenges" that require tailored solutions.

Chief among them is the functional unblinding problem. Psychedelics "cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days," the FDA notes — which means patients, therapists, monitors, and raters can often tell who received the active drug and who received placebo. That creates expectation bias in both directions: participants who experience perceptual changes may expect to benefit, while placebo recipients may expect not to. Designing well-controlled trials around that reality is one of the field's defining scientific challenges, and the guidance provides recommendations spanning chemistry, manufacturing, abuse potential assessment, and clinical pharmacology.

The document also acknowledges what makes these compounds therapeutically distinctive: they "can have both rapid-onset and long-term benefits after only one or a few doses" — a treatment paradigm fundamentally different from daily psychiatric medication, and one the regulatory framework must accommodate.

The September Hearing: Building the Post-Approval World

The public hearing announcement may be even more consequential than the guidance. The FDA is explicitly seeking input on four topics: provider training and credentialing, patient safety promotion, considerations for access, and best practices for data collection and standardization.

Read those topics carefully. They aren't questions about whether psychedelic therapy should exist. They're questions about how to operationalize it — who administers it, how patients are protected, how access is structured, and how real-world data gets captured. The agency was equally explicit about what it's not discussing: the merits of any pending application, CSA scheduling, legalization, or religious use.

This is what an agency does when it expects to approve something. You don't convene federal panelists and subject matter experts to discuss provider credentialing for a treatment class you intend to reject.

The momentum behind this is unmistakable. The guidance and hearing follow President Trump's executive order directing accelerated psychedelic research and access, the April HHS/FDA announcement on expediting therapeutic access for serious mental health conditions, a bipartisan letter from 32 members of Congress urging faster reviews, a new bill to codify the executive order into law, a proposed NDAA amendment extending DOD psychedelic research for six years, and legislation requiring the Pentagon to evaluate psilocybin's benefits for service members. Washington is not debating whether psychedelic medicine is coming. It's preparing for its arrival.

Compass Pathways: The Immediate Beneficiary

No company stands to gain more from regulatory clarity than Compass Pathways — because no company is closer to the finish line. Compass has completed both Phase 3 trials of COMP360 psilocybin for treatment-resistant depression, with COMP005 and COMP006 both meeting primary endpoints, and its critical 26-week durability data expected this quarter. The company has secured FDA agreement for a rolling NDA submission, holds a Commissioner's National Priority Voucher, and is targeting submission in Q4 2026 with launch readiness by year-end.

For Compass, the September hearing is effectively a planning session for its own commercial launch. Provider training, treatment-setting standards, and access frameworks are exactly the questions COMP360's REMS program and delivery model must answer. Sitting on $466 million in cash, Compass now has the FDA publicly building the administrative scaffolding its product will launch into.

Definium Therapeutics: Validation for the Blockbuster Data

Definium enters this moment with the strongest clinical results in the field — the Emerge Phase 3 trial of DT120 (lysergide) ODT delivered an 8.1-point placebo-adjusted MADRS improvement from a single dose, durable through 12 weeks, backed by a fresh $700 million raise led by four bulge-bracket banks. The finalized guidance directly de-risks Definium's remaining program: its confirmatory studies now proceed under a settled framework rather than draft recommendations, and the guidance's extensive treatment of functional unblinding — the primary methodological critique aimed at psychedelic trials — gives Definium a validated playbook for defending its data. When your Phase 3 results are this strong, the biggest remaining risk is regulatory ambiguity. The FDA just removed a meaningful piece of it.

AtaiBeckley: A Cleaner Path for the Pipeline

AtaiBeckley benefits across its entire portfolio. The company just dosed the final patient in Elumina, its 156-patient Phase 2b trial of VLS-01 — a DMT-based oral transmucosal film with a commercially attractive two-hour treatment session — with topline data expected in Q4. Its intranasal mebufotenin candidate BPL-003 is already in Phase 3 for TRD with Breakthrough Therapy Designation. For a company planning to advance VLS-01 into Phase 3 for major depressive disorder next year, finalized guidance means those pivotal trials get designed against known regulatory expectations from day one — no mid-program goalpost shifts. And the hearing's focus on supervised and supportive settings aligns precisely with atai's short-session thesis: if the FDA is standardizing what a psychedelic treatment setting looks like, the compound requiring two hours of monitoring instead of eight holds a structural advantage.

The Bottom Line

The psychedelic sector has raised over $1 billion in recent months on the strength of late-stage clinical data. What that capital was ultimately betting on is the moment the FDA stops treating psychedelics as a research curiosity and starts treating them as an approvable — and administrable — class of medicine.

That moment is now visible. Finalized guidance. A September hearing on post-approval logistics. An executive order, congressional pressure, and multiple bills pushing in the same direction. And three companies — Compass with its imminent NDA, Definium with its historic data and war chest, atai with its multi-asset pipeline — positioned to convert regulatory clarity into approved products.

The FDA just published the rulebook and scheduled the planning meeting. The first approvals are no longer a question of if. They're a question of which company gets there first — and all three are sprinting.

📈 Dog Walkers

Idaho Refuses To Move Forward

Idaho just reminded everyone why it remains the most prohibitionist state in America — and the deck may be getting stacked permanently.

The Secretary of State's Office announced that the Idaho Medical Cannabis Act initiative failed to qualify for the November ballot, falling short of the required 70,000+ signatures (6% of registered voters) and the geographic threshold of 6% in at least 18 of 35 legislative districts. The measure, spearheaded by the Natural Medicine Alliance of Idaho, would have allowed patients with conditions like cancer, PTSD, epilepsy, and chronic pain to access medical cannabis with physician documentation.

The group called the outcome disappointing but vowed to continue: "The demand Idahoans expressed through this campaign is not going away."

Here's the twist — voters will see a cannabis question in November, just not the one advocates wanted. Lawmakers placed a constitutional amendment on the ballot that would grant only the Legislature — not voters — the power to legalize marijuana or other psychoactive substances. If it passes, citizen-led cannabis initiatives in Idaho would be permanently foreclosed.

While Idaho testified against rescheduling at the ALJ hearing and every neighboring state has legalized in some form, the Gem State is moving to lock prohibition into its constitution. The contrast with the rest of the country has never been starker.

📺 Trade To Black

ALJ Hearing Nears the Finish Line | TTB Presented by Flowhub

• Curaleaf's Spain First: Curaleaf became the first company registered in Spain for standardized THC-dominant and CBD-dominant cannabis preparations under Royal Decree 903/2025, clearing the pathway for hospital-dispensed medical cannabis in a country of nearly 50 million people.

• Cannara Supply Deal: Curaleaf signed a long-term international supply agreement with Cannara Biotech worth up to C$21 million, positioning the Québec producer as a key bulk-flower supplier for Curaleaf's global medical markets — and accelerating Cannara's Valleyfield expansion by roughly a year.

• States Take the Stand: Michael Bronstein breaks down the final stretch of the ALJ hearing as Nebraska, Idaho, and Indiana present their testimony — the last designated opponents before the proceeding wraps, with federalism and enforcement arguments expected to dominate.

• The Finish Line: With the hearing concluding and post-hearing briefs ahead, Bronstein outlines what investors should watch next — the ALJ's recommendation timeline, the pending D.C. Circuit stay ruling, and how the two parallel tracks could converge to shape rescheduling's final outcome.